GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » LT-Debt-to-Total-Asset

Harbin Medisan Pharmaceutical Co (SZSE:002900) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Harbin Medisan Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Harbin Medisan Pharmaceutical Co's long-term debt to total assets ratio declined from Mar. 2023 (0.13) to Mar. 2024 (0.03). It may suggest that Harbin Medisan Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Harbin Medisan Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.07 0.13 0.07

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.13 0.06 0.07 0.03

Harbin Medisan Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Harbin Medisan Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=238.159/3442.984
=0.07

Harbin Medisan Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=90.529/3621.892
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Medisan Pharmaceutical Co  (SZSE:002900) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Harbin Medisan Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
SZSE:002923 SHSE:688799 SHSE:603538 SZSE:301201 SZSE:002864 SHSE:600829 SZSE:300436 SZSE:002940 SHSE:603168 SZSE:000919 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Website
http://www.medisan.com.cn
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines